Progress and potential of ferritin nanocages for cancer drug delivery
While HFn nanocages show strong promise in vaccine development, their application in cancer treatment faces significant translational challenges. These include limited human data, variability in receptor expression, rapid clearance, and the need for more representative models and scalable manufacturing, though certain untargeted HFn-based systems as Gd-HFn and Dox-HFn appear closer to clinical readiness.
Authors
- Marta Sevieri (ORCID: https://orcid.org/0000-0003-2017-641X)
- Fabio Corsi (ORCID: https://orcid.org/0000-0002-6469-4086)
- Serena Mazzucchelli (ORCID: https://orcid.org/0000-0001-6904-8895)
- Ilaria Tagliolini
- Francesca Gorgoglione
- Beatrice Bignami
- Valeria Giacobbo
Institutions
- University of Milan (IT)
- Istituti Clinici Scientifici Maugeri (IT)
Publication Details
- Journal
- Expert Opinion on Drug Delivery
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1080/17425247.2025.2584632
- Primary Topic
- Iron Metabolism and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Associazione Italiana per la Ricerca sul Cancro